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Over the past 2 decades, reduced-intensity conditioning allogeneic hematopoietic cell transplantation (RIC
HCT) has increased substantially. Many patients do not have fully HLA-matched donors, and the impact of
HLA mismatch on RIC HCT has not been examined in large cohorts. We analyzed 2588 recipients of 8/8
HLA-high resolution matched (n ¼ 2025) or single-locus mismatched (n ¼ 563) unrelated donor (URD) RIC
HCT from 1999 to 2011. Overall survival (OS) was the primary outcome. Secondary endpoints included
treatment-related mortality (TRM), relapse, disease-free survival (DFS), and acute/chronic graft-versus-host
disease (GVHD). Adjusted 1- and 3-year OS was better in 8/8- versus 7/8-matched recipients (54.7% versus
48.8%, P ¼ .01, and 37.4% versus 30.9%, P ¼ .005, respectively). In multivariate models 7/8 URD RIC HCT
recipients had more grades II to IV acute GVHD (RR ¼ 1.29, P ¼ .0034), higher TRM (RR ¼ 1.52, P < .0001), and
lower DFS (RR ¼ 1.12, P ¼ .0015) and OS (RR ¼ 1.25, P ¼ .0001), with no difference in relapse or chronic GVHD.
In subgroup analysis, inferior transplant outcomes were noted regardless of the HLA allele mismatched.
Previously reported permissive mismatches at HLA-C (C*03:03/C*03:04) and HLA-DP1 (based on
T celleepitope matching) were not associated with better outcomes. Although feasible, single-locus mismatch
in RIC URD HCT is associated with inferior outcomes.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION reduced-intensity conditioning (RIC) followed by unrelated
Increasing numbers of patients traditionally considered
ineligible for transplantation because of age, performance
status, or other comorbidities now commonly undergodgments on page 1788.
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ty for Blood and Marrow Transplantation.donor (URD) hematopoietic cell transplantation (HCT).
However, only about 30% to 75% of patients needing trans-
plantation will have an 8/8 HLA-matched (HLA-A, -B, -C,
-DRB1) URD [1,2]. Frequently a 7/8 single HLA-mismatched
donor is available for such patients. However, it is currently
unknown whether 7/8 URD RIC HCT recipients experience
inferior transplantation outcomes. In the context of mye-
loablative conditioning (MAC), HLA 7/8 mismatches increase
M.R. Verneris et al. / Biol Blood Marrow Transplant 21 (2015) 1783e17891784the incidence of acute graft-versus-host-disease (aGVHD)
and treatment-related mortality (TRM), resulting in inferior
overall survival (OS) [3-9]. Considering, however, that suc-
cessful RIC transplant procedures rely more on graft-versus-
leukemia reactions than after myeloablation and that
patients undergoing RIC URD HCT are more likely to be older
and/or have more comorbidities, it is important to examine
whether outcomes differ between 7/8-mismatched and fully
HLA-matched (8/8) URD RIC procedures.
A small number of studies have investigated the impact of
HLA mismatch in URD RIC HCT and have noted the impor-
tance of HLA-C locus mismatches. A retrospective report
from the Dana-Farber Cancer Institute compared HLA-C
antigen- and allele-mismatched donors to fully matched
donors and showed that mismatched recipients had signiﬁ-
cantly increased grades II to IV and III to IV aGVHD and TRM,
and worse 2-year OS rates [10]. In a Center for International
Blood and Marrow Transplant Research (CIBMTR) analysis of
HLA mismatches in URD peripheral blood transplantation
performed from 1999 to 2006, a subgroup of 673 URD RIC
transplantations was analyzed. Recipients of HLA-C antigen-
mismatched URD RIC transplants had signiﬁcantly reduced
survival [11]. However, HLA-C allele mismatches and other
locus mismatches were not identiﬁed as relevant, possibly
due to limited sample size. A prospective study of T-replete 1
to 2 locus HLA-mismatched RIC URD using peripheral blood
stem cells also described high rates of grades II to IV and III to
IV aGVHD, nonrelapse mortality, and 2-year OS rates [12].
To date, the question of whether HLA mismatching
impacts the success of URD RIC HCT has not been fully
addressed. This information is critical to optimize donor
selection and perhaps extend the utility of transplantation.
As well, data addressing this topic could constitute a baseline
comparator for any novel conditioning or GVHD regimens for
RIC URD recipients. Moreover, it is formally possible that HLA
mismatching may be beneﬁcial with respect to relapse,
especially in RIC. Therefore, a large registry analysis was
undertaken using the CIBMTR database to compare RIC URD
transplant in recipients of HLA 7/8 antigen or allele matched
transplants to recipients of 8/8 fully matched (HLA-A, -B, -C,
and -DRB1) transplants. In subgroup analysis, we determined
whether outcomes varied based on individual HLA locus
mismatch. Secondary aims were to determine whether there
was an interaction between disease risk and HLA mismatch
and whether mismatching between speciﬁc HLA-C alleles
(C*03:03/C*03:04) or HLA-DP (based on T celleepitope
matching) was permissive based on existing models in the
MAC setting [7,8,13,14].METHODS
Study Population
This study included patients reported to the National Marrow Donor
Program (NMDP)/CIBMTR who received a reduced-intensity or non-
myeloablative transplant from a URD between 1999 and 2011. Patients
receiving MAC were excluded. MAC was deﬁned as the following: single-
dose total body irradiation > 500 cGy or >800 cGy total in fractionated
doses, busulfan  9 mg/kg, melphalan with dose > 150 mg/m2, or thiotepa
dose> 10 mg/kg. The study population consisted of recipients who received
their ﬁrst bone marrow or peripheral blood URD transplantation for the
treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia
(AML), chronic myeloid leukemia (CML), or myelodysplastic syndrome
(MDS). Early-stage disease was deﬁned as AML or ALL in ﬁrst complete
remission, CML in ﬁrst chronic phase, and MDS subtype refractory anemia.
Intermediate-stage disease was deﬁned as AML or ALL in second or subse-
quent complete remission and CML in accelerated phase or second chronic
phase. Advanced-phase disease was deﬁned as AML in ﬁrst or higher relapse
or primary induction failure, CML in blast phase, and MDS subtypes
refractory anemia with excess blasts or in transformation.All surviving recipients included in this analysis provided informed
consent for participation in the NMDP research program. Research was
approved and conducted under the supervision of the NMDP Institutional
Review Board. A modeling process was used as previously described to
adjust for any bias introduced by exclusion of nonconsenting survivors
[5,15]. This adjustment is standard for all studies using NMDP data.
HLA Typing and Permissive Mismatch Analysis
High-resolution typing was performed as previously described for
HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 [16]. Low-resolution (serologic or
antigen-level) disparities were derived through conversion of DNA-based
typing to serologic equivalent according to the 2010 World Health Organi-
zation nomenclature for factors of the HLA system [17]. Mismatch at
HLA-DQ (and -DP) included only -DQB1 (and -DPB1), because there is strong
linkage disequilibrium between the alpha and beta subunits (>98%), and
-DQA1 and -DPA1 typing data were limited (not available for most cases in
the dataset). DQB1 and DPB1 data were available for 97% and 53% of the
population, respectively.
As previously described [18], the directionality of HLA mismatch was
considered for the analysis of GVHD and engraftment. Mismatches at
homozygous alleles were considered single mismatches. Donorerecipient
high-resolution HLA matching at HLA-A, -B, -C, and -DRB1 deﬁned an
8/8-matched pair. Allele- or antigen-level mismatch at one (7/8) of these loci
deﬁned the mismatch group of interest in the main analysis. Secondary
analyses examined the following: mismatch at HLA-DPB1 or -DQB1,
HLA-C*03:03/03:04 versus other -C allele or antigen mismatch [19], and
-DPB1 permissive versus nonpermissive mismatches according to T
celleepitope grouping, as previously reported [20]. The -DPB1 permissive
mismatch analysis was performed separately in 8/8 and 7/8 cases. These
analyses did not consider -DQB1, because -DQB1 mismatch was infrequent
(allele matched in 89% of cases).
Outcome Deﬁnitions
OS was deﬁned as time from HCT to death from any cause. Engraftment
was deﬁned as achieving an absolute neutrophil count of 500/mL for 3
consecutive days. TRM was deﬁned as death in continuous remission from
the primary malignancy. Disease-free survival (DFS) and relapse were
deﬁned per CIBMTR criteria [21]. Grades II to IV and III to IV aGVHD were
deﬁned by the Glucksberg scale [22], and chronic GVHD (cGVHD) was
deﬁned as limited or extensive cGVHD according to the Seattle criteria [23].
Statistical Analysis
For univariate analysis, probabilities for OS and DFS were calculated
using the Kaplan-Meier estimator with variance estimated by Greenwood’s
formula. Values for other outcomes were calculated according to cumulative
incidence. Death was considered a competing risk for all endpoints except
OS and DFS. Relapse and TRM were considered competing risks for each
other.
The association between number and type of HLA mismatches were
evaluated by Cox proportional hazards models adjusting for signiﬁcant
clinical covariates. Stepwise selection procedures were ﬁt to determine
which risk factors were related to a given outcome. All variables were tested
for the afﬁrmation of the proportional hazards assumption. Factors violating
the proportional hazards assumption were adjusted by using time-varying
covariates. Engraftment was reported as the cumulative incidence by day
100, with death as a competing risk. Interactions were checked between
each selected variable and themain effect. Covariates tested include disease,
disease status (early versus intermediate versus advanced), performance
status, patient age, donor age, donorerecipient sex match (FeM versus
other), donorerecipient cytomegalovirus match, graft source (peripheral
blood versus bone marrow), T cell depletion (antithymocyte globulin [ATG]/
alemtuzumab versus none), GVHD regimen (calcineurin inhibitorebased
versus other), and year of transplantation. Variables were categorized after
examination of the data or based on current evidence for relevant break-
points. The main analysis compares subgroups of HLA-mismatched pairs




From 1999 to 2011, 2588 patients underwent RIC URD
HCT from 144 centers and 12 countries and were reported to
the CIBMTR. Of these, 2025 patients received transplantation
from an HLA-matched unrelated donor (8/8 URD; HLA-A, -B,
-C, -DRB1) and 563 patients were transplanted with a
7/8 allele or antigen-matched URD. Patient and transplant
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recipients were older (P< .003), more likely white (P< .001),
and were transplanted with younger donors (34 versus 36
years, P ¼ .04). The 2 groups did not differ in disease status
(P ¼ .09), conditioning (P ¼ .92), graft type (P ¼ .42), donor
parity (P ¼ .07), use of total body irradiation (P ¼ .33), in vivoTable 1
Patient Characteristics
Variable 8/8 7/8 P
Number of patients 2025 563
Conditioning intensity .92
RIC 1601 (79) 444 (79)
Non-MAC 424 (21) 119 (21)
Recipient age .03
Median (range) 59 (18-81) 58 (19-76) .003
18-39 yr 215 (11) 67 (12)
40-54 yr 441 (22) 154 (27)
55-59 yr 397 (20) 107 (19)
60-64 yr 512 (25) 129 (23)
65 yr 460 (23) 106 (19)
Recipient race <.001
White 1925 (95) 508 (90)
African-American 44 (2) 30 (5)
Asian 23 (1) 8 (1)
Paciﬁc islander 1 (<1) 0
Native American 2 (<1) 3 (<1)
Other 2 (<1) 0
Unknown 28 (1) 14 (2)
Recipient gender .20
Male 1162 (57) 306 (54)
Female 863 (43) 257 (46)
Karnofsky score .06
<90% 728 (36) 233 (41)
90% 1190 (59) 303 (54)
Missing 107 (5) 27 (5)
Disease at HCT .11
AML 1318 (65) 372 (66)
ALL 151 (7) 44 (8)
CML 138 (7) 51 (9)
MDS 418 (21) 96 (17)
Disease status before HCT .09
Early 1038 (51) 268 (48)
Intermediate 365 (18) 124 (22)
Advanced 622 (31) 171 (30)
Graft type .42
Bone marrow 296 (15) 90 (16)
Peripheral blood 1729 (85) 473 (84)
Total body irradiation .33
No 1575 (78) 427 (76)
Yes 450 (22) 136 (24)
GVHD prophylaxis .74
FK506  others 1431 (71) 392 (70)
CSA  others 540 (27) 158 (28)
Others 54 (3) 13 (2)
In vivo T cell depletion .10
No 1194 (59) 310 (55)
Yes 831 (41) 253 (45)
Donor age <.001
Median (range) 34 (<1-221) 36 (19-221) .04
19-32 1017 (50) 231 (41)
32-49 890 (44) 288 (51)
50 114 (6) 40 (7)
Not available 4 (<1) 4 (<1)
Donor parity .07
Male or not parous 1674 (83) 444 (79)
Parous 307 (15) 100 (18)
Not available 44 (2) 19 (3)
Year of HCT <.001
1999-2002 104 (5) 48 (9)
2003-2006 578 (29) 190 (34)
2007-2011 1343 (66) 325 (58)
Median follow-up of
survivors, mo (range)
38 (3-149) 48 (3-145)
CSA indicates cyclosporine A.T cell depletion (P ¼ .10), or GVHD prophylaxis (P ¼ .74).
Considering the whole group (both 8/8 and 7/8 URD
patients), the conditioning intensity was more likely RIC
compared with non-MAC (79% versus 21%), and GVHD pro-
phylaxis wasmainly calcineurin inhibitorebased, with either
tacrolimus (70%) or cyclosporine A (27%). Themedian follow-
up for the 8/8 URD group was 38 months and for 7/8 URD
recipients 48 months; thus, 7/8 transplants were performed
earlier (P < .001).
Outcomes of URD 7/8 versus 8/8 URD RIC Transplants
Table 2 shows the univariate analysis comparing out-
comes between HLA 7/8 and HLA 8/8 RIC URD transplants. As
shown, 7/8 RIC URD recipients hadmore frequent grades II to
IV (43% versus 35%, P¼ .0018) and III to IV aGVHD (21% versus
13%, P< .001) and TRM (29% versus 20%, P< .001). There was
no associationwith relapse at 1, 3, or 5 years (P ¼ .73, P ¼ .78,
P ¼ .84, respectively) or cGVHD at 1, 3, or 5 years (P ¼ .3,
P ¼ .06, P ¼ .06, respectively). OS was worse in 7/8-matched
recipients at 1 year (48% versus 55, P ¼ .003), 3 years (30%
versus 38%, P < .001), and 5 years (22% versus 30%, P ¼ .004).
The consequences of a 7/8 URD RIC transplant were also
considered relative to 8/8 URD RIC transplants in multivari-
able analysis (Table 3). When adjusting for other signiﬁcant
covariates, the 7/8 URD RIC recipients were more likely to
develop grades II to IV aGVHD (relative risk [RR] ¼ 1.29;
P ¼ .003; Figure 1A). Grades III to IV aGVHD (RR ¼ 1.69;
P¼ .05) did notmeet the criteria for signiﬁcance. Higher TRM
(RR ¼ 1.52; P < .0001; Figure 1B), inferior DFS (RR ¼ 1.20;Table 2
Univariate Analysis Comparing Transplant Outcomes between Fully
Matched (HLA 8/8) Donors to Single-Locus (HLA 7/8) Mismatched Donors
Outcomes HLA 8/8 Donor HLA 7/8 Donor P








100-day 13 (11-15)% 21 (17-25)% <.001
cGVHD 1989 516
6 mo 27 (25-29)% 30 (26-34)% .018
1 yr 44 (42-47)% 44 (39-48)% .30
3 yr 50 (48-52)% 50 (45-54)% .064
5 yr 50 (48-53)% 50 (46-55)% .057
Extensive cGVHD 2000 518
6 mo 20 (18-22)% 24 (20-27)% .017
1 yr 33 (31-35)% 33 (29-37)% .27
3 yr 37 (35-39)% 38 (34-43)% .056
5 yr 37 (35-40)% 38 (34-43)% .056
Engraftment 2061 510
100-day 97 (96-98)% 94 (92-96)% .22
Relapse 2004 555
1 yr 36 (33-38)% 33 (29-37)% .78
3 yr 42 (40-44)% 39 (35-43)% .73
5 yr 44 (41-46)% 40 (36-45)% .84
TRM 2004 555
1 yr 20 (18-22)% 29 (25-33)% <.001
3 yr 27 (25-29)% 36 (31-40)% .0011
5 yr 31 (29-34)% 40 (35-44)% .0088
DFS 2004 555
1 yr 44 (42-47)% 39 (35-43)% .02
3 yr 31 (29-33)% 25 (21-29)% .01
5 yr 25 (23-27)% 20 (16-24)% .03
OS 2025 563
1 yr 55 (53-57)% 48 (44-52)% .003
3 yr 38 (35-40)% 30 (26-34)% <.001
5 yr 30 (27-32)% 22 (19-27)% .004
Prob indicates probability; CI, conﬁdence interval.
Table 3
Multivariable Analysis Comparing Outcomes between HLA 8/8 to HLA 7/8
Donors
Variable RR 95% CI P
Lower Limit Upper Limit
aGVHD grades II-IV .003
8/8 allele match 1
7/8 allele match 1.29 1.09 1.53
aGVHD grades III-IV .05
8/8 allele match 1
7/8 allele match 1.69 1.00 3.36
cGVHD .15
8/8 allele match 1
7/8 allele match 1.11 .96 1.28
TRM <.0001
8/8 allele match 1
7/8 allele match 1.52 1.29 1.79
Relapse .92
8/8 allele match 1
7/8 allele match 1.007 .87 1.17
DFS .0015
8/8 allele match 1
7/8 allele match 1.20 1.07 1.34
OS .0001
8/8 allele match 1
7/8 allele match 1.25 1.12 1.40
Multivariable models also included the following covariates: aGVHD grades
II-IV: GVHD prophylaxis, graft type, in vivo T cell depletion, DPB1 matching;
aGVHD grades III-IV: GVHD prophylaxis, total body irradiation, in vivo T cell
depletion; cGVHD: year of transplant, in vivo T cell depletion; TRM: graft
type, recipient age, Karnofsky performance score, disease, GVHD prophy-
laxis; Relapse: Karnofsky performance score, disease status, conditioning
intensity, in vivo T cell depletion; DFS: Karnofsky performance score, dis-
ease status, conditioning intensity; OS: graft type, recipient age, Karnofsky
performance score, donor age, and disease status.
Figure 1. Impact of single-allele mismatch on (A) aGVHD grades II to IV
and cumulative incidences of (B) TRM and (C) OS. MMUD indicates mis-
matched unrelated donor; MUD, matched unrelated donor.
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were seen in 7/8 compared with 8/8 URD RIC recipients.
The impact of allele- versus antigen-level mismatches in
aggregate was also assessed. Comparing single-allele mis-
matches to single-antigen mismatches showed no differ-
ences in TRM (RR ¼ 1.37; P ¼ .27) or OS (RR ¼ .74; P ¼ .08).
Whether ATG mitigated the negative impact of 7/8 donors
was also investigated. However, there was no interaction
between ATG and HLA matching; thus, although ATG may be
improving outcomes in recipients of 7/8-matched donors
(compared with no ATG), it is not abrogating the negative
effect of mismatch.
Potential differences in the association of HLA
mismatching with disease status before transplantation
were also considered, as described in myeloablative HLA-
mismatched transplantation [5]. There was no interaction
between disease status and HLA matching in the OS analysis
(P ¼ .42). Survival differences at 3 years based on HLA mis-
matching were not statistically different among early-stage
disease (43% HLA matched versus 38% HLA mismatched),
intermediate-stage disease (40% versus 31%), and advanced-
stage disease (27% versus 19%).
Individual Locus Mismatch and Patient Outcomes
We investigated whether mismatching at speciﬁc HLA
loci impacted RIC URD transplant outcomes. Mismatching at
HLA-DQ and -DP were not associated with TRM, aGVHD,
relapse, DFS, and OS (not shown). Recently, certain HLA-DP
mismatches have been identiﬁed as being permissive (or
nonpermissive) on the basis of T celleepitope matching [20].
Patients with available HLA-DP typing (n ¼ 1056) were
categorized as either matched (n ¼ 160), mismatched
permissive (n ¼ 498), or mismatched nonpermissive(n ¼ 398). In multivariable analysis, nonpermissive mis-
matches were not associated with greater aGVHD grades II to
IV (P ¼ .26) or grades III to IV (P ¼ .57), cGVHD (P ¼ .79), TRM
(P ¼ .3), relapse (P ¼ .47), DFS (P ¼ .8), or OS (P ¼ .45).
Similarly, HLA C*03:03/C*03:04 mismatches have been
reported to be permissive in myeloablative transplantation
[19]. Only a small numbers (50 to 59, depending on the
outcome measure) were available to assess whether the
HLA-C*03:03/C*03:04 mismatch was better tolerated than
other HLA-C mismatches or other allele mismatches (HLA-A,
-B, or -DRB1). No differences were seen in TRM, GVHD, DFS,
or OS (not shown).
The number of patients in each HLA locus mismatch
group became relatively small, ranging from 52 to 219 pa-
tients depending on the group and the transplant outcome
analyzed. Mismatches at HLA-A and -C were more common
than HLA-B or -DRB1 (33% versus 39% versus 14% versus 13%,
Table 4
Graft Matching Characteristics
Variable 8/8 7/8 P
High-resolution matching for HLA-A,
-B, -C, -DRB1
Fully matched 2025 0
Single MM at -A 0 188 (33)
Single MM at -B 0 81 (14)
Single MM at -C 0 219 (39)
Single MM at -DRB1 0 75 (13)
Low-resolution matching for HLA-A,
-B, -C, -DRB1
Fully matched 2025 197 (35)
Single MM at -A 0 143 (25)
Single MM at -B 0 36 (6)
Single MM at -C 0 170 (30)
Single MM at -DRB1 0 17 (3)
DQB1 match <.001
Allele matched 1804 (89) 488 (87)
Single-allele mismatch 70 (3) 36 (6)
Double-allele mismatch 0 1 (<1)
Single-antigen mismatch 71 (4) 27 (5)
One-allele and 1-antigen mismatch 2 (<1) 1 (<1)
Double-antigen mismatch 1 (<1) 1 (<1)
Missing 77 (4) 9 (2)
DPB1 match .06
Allele matched 160 (8) 41 (7)
Single-allele mismatch 559 (28) 175 (31)
Double-allele mismatch 337 (17) 110 (20)
Missing 969 (48) 237 (42)
MM indicates mismatch.
Values in parentheses are percentages.
Table 5
Transplant Outcomes Based on Allele Locus Mismatches






aGVHD grades II-IV .025
8/8 allele match 1366 1
Single MM at -A 127 1.1 .52 .82 1.47
Single MM at -B 63 1.27 .24 .85 1.90
Single MM at -C 175 1.40 .005 1.11 1.77
Single MM at -DRB1 52 1.46 .08 .96 2.22
aGVHD grades III-IV .0004
8/8 allele match 1371 1
Single MM at -A 128 1.75 .005 1.18 2.58
Single MM at -B 63 1.72 .06 .98 3.01
Single MM at -C 176 1.43 .07 .98 2.09
Single MM at -DRB1 52 2.49 .001 1.45 4.30
TRM <.0001
8/8 allele match 2004 1
Single MM at -A 186 1.62 .0002 1.25 2.09
Single MM at -B 80 2.26 <.0001 1.63 3.14
Single MM at -C 216 1.32 .03 1.03 1.70
Single MM at -DRB1 73 1.18 .45 .77 1.79
DFS .0004
8/8 allele match 2004 1
Single MM at -A 186 1.26 .009 1.06 1.51
Single MM at -B 80 1.51 .001 1.18 1.93
Single MM at -C 216 1.18 .049 1.00 1.38
Single MM at -DRB1 73 .85 .29 .63 1.15
OS <.0001
8/8 allele match 2025 1
Single MM at -A 188 1.43 <.0001 1.20 1.71
Single MM at -B 81 1.57 .0005 1.22 2.02
Single MM at -C 219 1.13 .16 .96 1.34
Single MM at -DRB1 75 .97 .82 .71 1.31
Multivariable models also included the following covariates: aGVHD grades
II-IV: GVHD prophylaxis, graft type, in vivo T cell depletion; aGVHD grades
III-IV: GVHD prophylaxis, total body irradiation, in vivo T cell depletion;
cGVHD: year of transplant, in vivo T cell depletion; TRM: graft type, recip-
ient age, Karnofsky performance score, disease, GVHD prophylaxis; Relapse:
Karnofsky performance score, disease status, conditioning intensity, in vivo
T cell depletion; DFS: Karnofsky performance score, disease status, condi-
tioning intensity; OS: graft type, recipient age, Karnofsky performance
score, donor age, and disease status.
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at a particular locus (HLA-A, -B, -C, or -DRB1) was detected
for either relapse or cGVHD. Mismatching at HLA-A was not
associated with grades II to IV aGVHD but did signiﬁcantly
increase grades III to IV aGVHD (RR¼ 1.75; P¼ .005) and TRM
(RR ¼ 1.62; P ¼ .0002) and lower DFS (RR ¼ 1.26; P ¼ .009)
and OS (RR ¼ 1.43; P < .0001). Single-allele mismatches at
HLA-B showed no association with aGVHD grades II to IV or
III to IV but were strongly associated with higher TRM (RR ¼
2.26; P < .0001) and lower DFS (RR ¼ 1.51, P ¼ .001) and OS
(RR ¼ 1.57; P ¼ .0005). HLA-C mismatched pairs had
increased grades II to IV aGVHD (RR ¼ 1.4; P ¼ .005) but not
grades III to IV aGVHD, TRM, DFS, or OS. Finally, HLA-DRB1
mismatches were associated with increased grades III to IV
aGVHD (RR ¼ 2.49; P ¼ .001) but not grades II to IV aGVHD,
TRM, DFS, or OS. Collectively, these results show that mis-
matching at any loci (HLA-A, -B, and -C or -DRB1) was
associated with at least 1 inferior transplant outcome after
RIC URD. Adjusted multivariable outcomes for single-allele
mismatched recipients are shown in Table 5.DISCUSSION
A signiﬁcant proportion of patients lack a fully HLA-
matched URD for transplantation, and 1 option is to use
HLA partially matched URDs. Over the past 10 to 15 years a
number of large studies have shown that MAC and HLA-
mismatched URD RIC transplantation results in inferior
transplant outcomes [3-9]. However, over the past 2 decades,
use of RIC has steadily increased worldwide. With this
change, it is important to identify the risks and beneﬁts of
partially HLA-matched URD transplantation. There are a
number of fundamental differences between RIC and MAC
transplants, including the degree of tissue injury induced by
the conditioning regimen, the kinetics of donor engraftment,
and immunologic reconstitution. As well, patients undergo-ing RIC tend to be older, have worse performance status, and
are more likely to have chronic or indolent malignancies
relative to MAC-treated patients. In this large international
registry study we demonstrate that single-allele mismatched
(7/8) RIC URD transplantation resulted in signiﬁcantly
inferior outcomes when compared with a cohort of 8/8
HLA-matched donors. In particular, 7/8-mismatched RIC URD
recipients experienced greater rates of aGVHD (grades II to
IV) and TRM and inferior DFS and OS. RIC URD 7/8 recipients
had an approximately 6.5% reduction in OS at 3 years
comparedwith RIC URD 8/8 recipients. These decrements are
similar to, but perhaps lower than, those observed in the
MAC setting where mismatched donors yielded a 9% to 14%
reduction in OS [5,6,11]. Thus, despite inherent differences
between RIC and MAC, the overall impact of single-locus
mismatch appears to be similar.
The other goal of this analysis was to determine the
impact of mismatching at individual HLA loci on RIC trans-
plant outcomes to help identify better mismatched donors.
Despite being a registry study of >2500 patients, when the
groups were analyzed based on individual locus mismatch
(at HLA-A, -B, -C, and -DRB1), patient numbers were reduced,
and, thus, caution should be used in interpreting negative
results because power may be limited. Importantly, all
mismatch groups had at least 1 transplant outcome that was
inferior to fully matched recipients. These ﬁndings contrast
M.R. Verneris et al. / Biol Blood Marrow Transplant 21 (2015) 1783e17891788with those of Woolfrey et al. [11], who in a CIBMTR RIC URD
subgroup analysis (n ¼ 673) reported that only HLA-C anti-
gen mismatches had worse outcomes. In the current study,
we had greater power to address this question and found
that mismatching at any locus resulted in inferior transplant
outcomes compared with fully matched donors. Of note,
there was only 19% overlap between these 2 CIBMTR studies.
A number of interesting ﬁndings differed when compared
with prior MAC studies. First, we were surprised to observe
that mismatches in HLA-DRB1 (n ¼ 75) were as well toler-
ated as HLA class I mismatches. In fact, in multivariable
analysis HLA-DRB1 mismatches were not associated with
reductions in DFS or OS, contrasting with prior data in the
MAC data [6,7]. Also interesting was that HLA-B mismatches
were not associated with aGVHD grades II to IV or III to IV but
were strongly associated with TRM. In contrast, we found
that mismatches at HLA-C were associated with aGVHD
grades II to IV and TRM but not with severe grades III to IV
aGVHD. Acknowledging the caveat of small patient numbers,
the current results suggest the use of HLA-C or -DRB1
mismatched donors may be preferable over mismatches at
HLA-A and/or -B for RIC URD transplantation.
Although MHC disparity may drive allogeneic reactions
that may protect against relapse, there was no reduction in
relapse for the HLA-mismatched RIC cohort. Prior studies
showed that disease status modiﬁed outcomes of HLA-
mismatched MAC transplants, with advanced disease
patients not experiencing as large an absolute decrement in
survival with HLA mismatching as low-risk patients [24]. In
this analysis there was no interaction between disease status
and HLA-matching status. Although on the one hand relapse
rates are generally higher in the RIC setting and this might
have allowed us to more readily detect an association of HLA
mismatching with relapse, this study was not speciﬁcally
designed to address this question. Thus, the disease groups
were heterogeneous, making it difﬁcult to identify any pro-
tective effect of HLA mismatching. As well, HLA mismatching
was strongly associated with the development of aGVHD.
Therefore, any beneﬁt of HLA mismatching (ie, increased
graft-versus-leukemia) might have been blunted by GVHD
therapy. These ﬁndings are consistent with other studies that
fail to show differences in relapse when comparing sibling
donor to URD stem cell sources, where the latter might be
expected to have more alloreactivity but also increased
aGVHD [25,26].
In summary, in the largest study to examine the associ-
ation of HLA mismatching with RIC URD transplant out-
comes, we found that compared with 8/8 HLA-matched
recipients, a single-locus mismatch (ie, 7/8 match) was
associated with a considerable reduction in survival, mainly
due to increased rates of aGVHD and TRM, with no change in
relapse rates. We also found that mismatching at individual
HLA loci had differential negative impacts on transplant
outcomes, but caution is needed in interpreting these ﬁnd-
ings because the sample size of each subgroup is relatively
small. Nonetheless, recipients of mismatched RIC URD
donors showed inferior outcomes compared with fully
matched donor transplants. Overall, these ﬁndings show that
although mismatched RIC URD transplantation is feasible, it
comes at a signiﬁcant cost in the form of toxicity and
reduction in survival. Novel regimens to improve 7/8 URD
RIC HCT outcomes are needed.
ACKNOWLEDGMENTS
Financial disclosure: The authors have nothing to disclose.Conﬂict of interest statement: There are no conﬂicts of
interest to report.REFERENCES
1. Foeken LM, Green A, Hurley CK, et al. Monitoring the international use
of unrelated donors for transplantation: the WMDA annual reports.
Bone Marrow Transplant. 2010;45:811-818.
2. Petz LD, Spellman SS, Gragert L. The underutilization of cord blood
transplantation: extent of the problem, causes, and methods improve-
ment. In: Broxmeyer HE, editor. Cord Blood: Biology, Transplantation,
Banking, and Regulation. Bethesda, MD: AABB Press; 2011. p. 557-584.
3. Morishima Y, Sasazuki T, Inoko H, et al. The clinical signiﬁcance
of human leukocyte antigen (HLA) allele compatibility in patients
receiving a marrow transplant from serologically HLA-A, HLA-B, and
HLA-DR matched unrelated donors. Blood. 2002;99:4200-4206.
4. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA
alleles on clinical outcome after transplantation of hematopoietic stem
cells from an unrelated donor. Japan Marrow Donor Program. N Engl J
Med. 1998;339:1177-1185.
5. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA
matching contributes to the success of unrelated donor marrow
transplantation. Blood. 2007;110:4576-4583.
6. Loiseau P, Busson M, Balere ML, et al. HLA Association with hemato-
poietic stem cell transplantation outcome: the number of mismatches
at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall
survival. Biol Blood Marrow Transplant. 2007;13:965-974.
7. Petersdorf EW, Gooley T, Malkki M, Horowitz M. Clinical signiﬁcance
of donor-recipient HLA matching on survival after myeloablative
hematopoietic cell transplantation from unrelated donors. Tissue
Antigens. 2007;69(Suppl 1):25-30.
8. Shaw BE, Gooley TA, Malkki M, et al. The importance of HLA-DPB1 in
unrelated donor hematopoietic cell transplantation. Blood. 2007;110:
4560-4566.
9. Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated
donor haemopoietic stem-cell transplantation in adults with acute
leukaemia: a retrospective analysis. Lancet Oncol. 2010;11:653-660.
10. Ho VT, Kim HT, Liney D, et al. HLA-C mismatch is associated with
inferior survival after unrelated donor non-myeloablative hemato-
poietic stem cell transplantation. Bone Marrow Transplant. 2006;37:
845-850.
11. Woolfrey A, Klein JP, Haagenson M, et al. HLA-C antigen mismatch is
associated with worse outcome in unrelated donor peripheral blood
stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:
885-892.
12. Nakamae H, Storer BE, Storb R, et al. Low-dose total body irradiation
and ﬂudarabine conditioning for HLA class I-mismatched donor stem
cell transplantation and immunologic recovery in patients with
hematologic malignancies: a multicenter trial. Biol Blood Marrow
Transplant. 2010;16:384-394.
13. Lauterbach N, Crivello P, Wieten L, et al. Allorecognition of HLA-DP
by CD4þ T cells is affected by polymorphism in its alpha chain. Mol
Immunol. 2014;59:19-29.
14. Fleischhauer K, Fernandez-Vina MA, Wang T, et al. Risk associations
between HLA-DPB1 T-cell epitope matching and outcome of unrelated
hematopoietic cell transplantation are independent of HLA-DPA1. Bone
Marrow Transplant. 2014;49:1176-1183.
15. Farag SS, Bacigalupo A, Eapen M, et al. The effect of KIR ligand
incompatibility on the outcome of unrelated donor transplantation: a
report from the Center for International Blood and Marrow Transplant
Research, the European Blood and Marrow Transplant Registry, and the
Dutch registry. Biol Blood Marrow Transplant. 2006;12:876-884.
16. Spellman S, Setterholm M, Maiers M, et al. Advances in the selection of
HLA-compatible donors: reﬁnements in HLA typing and matching over
the ﬁrst 20 years of the National Marrow Donor Program Registry. Biol
Blood Marrow Transplant. 2008;14:37-44.
17. Marsh SG, Albert ED, Bodmer WF, et al. Nomenclature for factors of the
HLA system, 2010. Tissue Antigens. 2010;75:291-455.
18. Hurley CK, Woolfrey A, Wang T, et al. The impact of HLA unidirec-
tional mismatches on the outcome of myeloablative hematopoietic
stem cell transplantation with unrelated donors. Blood. 2013;121:
4800-4806.
19. Fernandez-Vina MA, Wang T, Lee SJ, et al. Identiﬁcation of a permis-
sible HLA mismatch in hematopoietic stem cell transplantation. Blood.
2014;123:1270-1278.
20. Fleischhauer K, Shaw BE, Gooley T, et al. Effect of T-cell-epitope
matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-
cell transplantation: a retrospective study. Lancet Oncol. 2012;13:
366-374.
21. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I
and class II high-resolution matching on outcomes of unrelated donor
bone marrow transplantation: HLA-C mismatching is associated with a
strong adverse effect on transplantation outcome. Blood. 2004;104:
1923-1930.
M.R. Verneris et al. / Biol Blood Marrow Transplant 21 (2015) 1783e1789 178922. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of
graft-versus-host disease in human recipients of marrow from HLA-
matched sibling donors. Transplantation. 1974;18:295-304.
23. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host
syndrome in man. A long-term clinicopathologic study of 20 Seattle
patients. Am J Med. 1980;69:204-217.
24. Pidala J, Lee SJ, Ahn KW, et al. Nonpermissive HLA-DPB1 mismatch
increases mortality after myeloablative unrelated allogeneic hemato-
poietic cell transplantation. Blood. 2014;124:2596-2606.25. Weisdorf DJ, Nelson G, Lee SJ, et al. Sibling versus unrelated donor
allogeneic hematopoietic cell transplantation for chronic myelogenous
leukemia: reﬁned HLA matching reveals more graft-versus-host dis-
ease but not less relapse. Biol Blood Marrow Transplant. 2009;15:
1475-1478.
26. Ringden O, Pavletic SZ, Anasetti C, et al. The graft-versus-leukemia
effect using matched unrelated donors is not superior to HLA-
identical siblings for hematopoietic stem cell transplantation. Blood.
2009;113:3110-3118.
